Clinical Trials

350 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06545331 2026-04-15

DELTA-101

BreastGastrointestinalThoracic

396 enrolled

Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT06806852 2026-04-15

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

90 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04958239 2026-04-14

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

151 enrolled

Neoplasms

NCT05382559 2026-04-14

A Study of ASP3082 in Adults With Advanced Solid Tumors

681 enrolled

Neoplasm Metastasis, Neoplasms

NCT06333951 2026-04-13

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

500 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06960395 2026-04-13

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

450 enrolled

Solid Tumor Malignancies

NCT07166601 2026-04-13

TITER

77 enrolled

GenitourinaryThoracic

Medullary cystic kidney disease 1, Carcinoma, Non-Small-Cell Lung

NCT07247110 2026-04-13

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

250 enrolled

Neoplasms

NCT06057038 2026-04-08

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

42 enrolled

Malignant Solid Tumor

NCT04389632 2026-04-07

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

1,006 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT06004245 2026-04-07

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

280 enrolled

Colorectal Neoplasms, Microsatellite Instability

NCT07484022 2026-04-07

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

37 enrolled

Genitourinary

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT05614102 2026-03-31

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

DermatologicGenitourinaryThoracic

284 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT06600321 2026-03-31

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

158 enrolled

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

NCT06188208 2026-03-30

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors

Phase 1 Terminated

132 enrolled

Neoplasms

NCT06868732 2026-03-30

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

288 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Advanced Non-small Cell Lung Cancer

NCT04234113 2026-03-27

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Phase 1 Terminated

115 enrolled 43 charts

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05017012 2026-03-27

MK-3475A-C18

72 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05763004 2026-03-27

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

140 enrolled

Solid Tumor, Adult

NCT06561685 2026-03-27

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

340 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis

NCT04670679 2026-03-25

FLAGSHP-1

GastrointestinalHead & NeckSarcoma

90 enrolled

Squamous Cell Carcinoma of Head and Neck, Chordoma, Neoplasm Metastasis, Neoplasms, Noonan Syndrome, Colorectal Neoplasms

NCT05838768 2026-03-24

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

123 enrolled

Turcot syndrome, Neoplasm Metastasis, Colorectal Neoplasms

NCT06462794 2026-03-24

First In Human Study of CX-801 in Advanced Solid Tumors

121 enrolled

Solid Tumor, Adult

NCT05614739 2026-03-23

FORAGER-1

535 enrolled

Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms, Urologic Neoplasms

NCT06917079 2026-03-23

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Phase 1 Enrolling by invitation

387 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT07218003 2026-03-23

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

149 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05537740 2026-03-20

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

BreastDermatologicHead & NeckThoracic

129 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms

NCT07182591 2026-03-20

A Study of DS5361b in Participants With Advanced Solid Tumors

192 enrolled

Advanced Solid Tumor

NCT04443088 2026-03-18

KEYNOTE-E12

78 enrolled

Neoplasm Metastasis, Neoplasms

NCT05954312 2026-03-18

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

290 enrolled

DermatologicGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma Of Esophagus, Neoplasms

NCT06108479 2026-03-18

Study of DF6215 in Patients With Advanced Solid Tumors

Phase 1 Completed

35 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms

NCT06894771 2026-03-16

MK-4700-001

Phase 1 Completed

5 enrolled

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

NCT07475572 2026-03-16

A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma

Phase 1 Not yet recruiting

120 enrolled

Dermatologic

Melanoma

NCT05853367 2026-03-13

MK-0472-001

178 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT06607185 2026-03-13

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors